Paper Details

  1. Home
  2. Paper Details

Influence of the Vitreoretinal Interface on the Treatment with Anti-VEGF for Exudative Age-Related Macular Degeneration.

Author: CachuloMaria da Luz, CamiloEduardo Nery Rossi, FonsecaCristina, GilJoão, GilPedro, LaínsInês, OliveiraNuno, RaimundoMiguel, SilvaRufino

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the influence of the vitreoretinal interface on the outcomes of different ranibizumab regimens for exudative age-related macular degeneration. Patients with posterior vitreous detachment (PVD) showed greater visual improvement than those without PVD, especially in the pro-re-nata (PRN) regimen. However, monthly dosing provided similar outcomes for both groups. This suggests that PRN should be avoided in the absence of PVD, and treat and extend (T&E) might be an alternative.
Paper Details　
Original Abstract of the Article :
PURPOSE: To investigate the influence of the vitreoretinal interface on the outcomes of different ranibizumab regimens for exudative age-related macular degeneration. METHODS: We conducted a retrospective subanalysis of 2 prospective clinical trials. Patients were treated with ranibizumab for 12 mo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000488010

データ提供：米国国立医学図書館（NLM）

The Vitreoretinal Interface: A Crucial Player in Age-Related Macular Degeneration Treatment

This study delves into the fascinating world of ophthalmology, specifically focusing on the treatment of exudative age-related macular degeneration (AMD). This condition, characterized by fluid leakage in the macula, can significantly impair vision. The researchers investigated the impact of the vitreoretinal interface, the boundary between the vitreous gel and the retina, on the effectiveness of various ranibizumab treatment regimens. They employed a retrospective subanalysis of two prospective clinical trials, analyzing data from 64 eyes of 64 patients treated with ranibizumab for 12 months using three different regimens: pro-re-nata (PRN), treat and extend (T&E), and monthly. The study revealed a crucial finding: the absence of posterior vitreous detachment (PVD) had a negative impact on visual improvement, particularly with the PRN regimen. However, monthly dosing provided similar outcomes to patients with PVD, suggesting a potential alternative treatment strategy.

A Regimen-Dependent Effect of the Vitreoretinal Interface

The results clearly demonstrate the influence of the vitreoretinal interface on AMD treatment outcomes, particularly for the PRN regimen. It seems that the presence of PVD facilitates the effectiveness of ranibizumab treatment, possibly due to improved drug penetration or reduced inflammation. This insight is particularly valuable for clinicians who need to tailor treatment plans to individual patient characteristics.

Navigating the Sands of AMD Treatment

This study highlights the importance of considering the vitreoretinal interface when choosing treatment regimens for AMD. It's like navigating the vast desert landscape - understanding the nuances of the terrain is essential for successful navigation. For patients with AMD, the presence or absence of PVD can significantly impact treatment outcomes. This information empowers patients to make informed decisions regarding their treatment options, collaborating with their ophthalmologists to find the optimal path to better vision.

Dr. Camel's Conclusion

This research provides valuable insights into the complexities of treating AMD, emphasizing the importance of considering individual patient factors. It's like searching for a hidden oasis in the desert - we need to meticulously explore different approaches and adapt our strategies based on the unique challenges presented by each patient. The findings underscore the need for continued research to optimize AMD treatment, improving the lives of countless individuals affected by this debilitating disease.
Date :
  1. Date Completed 2018-06-22
  2. Date Revised 2018-06-22
Further Info :

Pubmed ID

29734180

DOI: Digital Object Identifier

10.1159/000488010

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.